# OnCo record espac-5 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/espac-5/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "espac-5", "ISRCTN89500674" ;
  schema:name "ESPAC-5"@en ;
  schema:alternateName "ESPAC5"@en, "ESPAC-5F"@en ;
  schema:description "ESPAC-5 randomised people whose pancreatic cancer sat on the border of being removable between going straight to surgery and having two months of chemotherapy or chemoradiotherapy first; those treated first were far more likely to be alive a year later, 78 to 84 percent with chemotherapy against 39 percent with immediate surgery, which supports treating before operating in borderline disease."@en ;
  schema:url <https://onco.cc/trials/espac-5/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S2468-1253(22)00348-X>, <https://www.isrctn.com/ISRCTN89500674> ;
  onco:status "positive" ;
  onco:tag "soc-trials" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/borderline-resectable-pdac/>, <https://onco.cc/cancers/pancreatic/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/imrt-igrt/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/folfirinox/> ;
  onco:institutions <https://onco.cc/institutions/liverpool-hpb-centre/> ;
  onco:trials <https://onco.cc/trials/alliance-a021501/>, <https://onco.cc/trials/preopanc-2/> ;
  onco:people <https://onco.cc/people/paula-ghaneh/>, <https://onco.cc/people/daniel-palmer/>, <https://onco.cc/people/chris-halloran/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-espac-5-neoadjuvant-borderline-resectable-pancreatic-lancet-gastro-hep-2023/> .